What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?

Quest Diagnostics' (DGX) shares have risen 25.6% over the past year, outperforming its industry and the S&P 500, driven by growth in advanced diagnostics, strategic acquisitions like LifeLabs and PathAI Diagnostics, and efficiency gains from AI and automation. First quarter 2025 results benefited from double-digit growth in advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health areas, with brain health seeing high demand for Alzheimer's risk assessment tests. However, Quest's high long-term debt of $5.68 billion and potential regulatory changes pose concerns, though 2025 and 2026 EPS are projected to increase 8.6% and 8.2%, respectively.

Analysis

Quest Diagnostics (DGX) has demonstrated significant market outperformance, with its shares rallying 25.6% over the past year, substantially exceeding the industry's 5.5% rise and the S&P 500's 12% gain. This momentum is primarily attributed to robust growth in its Advanced Diagnostics portfolio, particularly in advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health, all of which reported solid double-digit growth in Q1 2025. Notably, AD-detect blood tests for Alzheimer's disease risk assessment are experiencing impressive demand. Strategic acquisitions, such as LifeLabs and PathAI Diagnostics, are key contributors to revenue growth and the integration of AI for enhanced diagnostic capabilities; the company completed eight acquisitions in 2024. Furthermore, Quest Diagnostics is actively pursuing operational efficiencies through AI, automation, and its Invigorate cost-savings program, targeting 3% annual cost savings, and recently collaborated with Google Cloud for data management and GenAI applications. Despite these strengths and a positive outlook with projected EPS increases of 8.6% to $9.70 for 2025 and 8.2% to $10.50 for 2026, and revenue growth of 9.2% to $10.78 billion for 2025, concerns persist regarding the company's solvency. Quest holds substantial long-term debt of $5.68 billion against a cash position of only $188 million as of Q1 2025, and potential healthcare regulatory shifts pose an additional risk, reflected in its current Zacks Rank #3 (Hold).

Key Decisions for Investors

• Investors should acknowledge Quest Diagnostics' strong growth drivers in advanced diagnostics and successful M&A strategy, which support its positive earnings and revenue outlook, but temper enthusiasm with the company's current Zacks Rank #3 (Hold) status.
• Careful monitoring of the company's high leverage, with $5.68 billion in long-term debt versus $188 million in cash, is crucial, as this presents a significant solvency concern despite ongoing operational improvements.
• Consider tracking the execution of its AI and automation initiatives, including the Google Cloud collaboration, for sustained cost savings and productivity gains, alongside any potential impacts from healthcare regulatory changes on its business model and reimbursement rates.
• Evaluate the balance between the robust operational momentum, particularly the double-digit growth in advanced diagnostics and accretive acquisitions, against the financial risks and regulatory uncertainties before adjusting positions.